Shopping Cart
Remove All
Your shopping cart is currently empty
LSKL, Inhibitor of Thrombospondin TSP-1 2TFA
Copy Product Info
😃Good
Catalog No. T7676
LSKL, Inhibitor of Thrombospondin TSP-1 2TFA is activation of TGF-β .
LSKL, Inhibitor of Thrombospondin TSP-1 2TFA
Copy Product Info😃Good
Purity: 99.75%
Catalog No. T7676
LSKL, Inhibitor of Thrombospondin TSP-1 2TFA is activation of TGF-β .
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 2 mg | $37 | In Stock | - | |
| 5 mg | $52 | In Stock | - | |
| 10 mg | $81 | In Stock | - | |
| 25 mg | $148 | In Stock | - | |
| 50 mg | $229 | In Stock | - | |
| 100 mg | $352 | In Stock | - | |
| 200 mg | $492 | Inquiry | Inquiry | |
| 1 mL x 10 mM (in DMSO) | $89 | In Stock | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:99.75%
Appearance:Viscous
Color:White
Contact us for more batch information
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | LSKL, Inhibitor of Thrombospondin TSP-1 2TFA is activation of TGF-β . |
| In vivo | Administration of LSKL peptide attenuated Smad2 phosphorylation at 6 h. S-phase entry of hepatocytes was accelerated at 24 and 48 h by LSKL peptide, which resulted in faster recovery of the residual liver and bodyweight.?Haematoxylin and eosin tissue staining and blood biochemical examinations revealed no significant adverse effects following the two LSKL peptide administrations.?In the clinical setting, plasma TSP-1 levels were lowest on the first day after hepatectomy.?However, plasma TSP-1 levels at this stage were significantly higher in patients with subsequent liver dysfunction compared with levels in those without liver dysfunction following hepatectomy |
| Animal Research | Mice were operated on with a 70 per cent hepatectomy or sham procedure. Operated mice received either LSKL peptide or normal saline intraperitoneally at abdominal closure and 6 h after hepatectomy. Perioperative plasma TSP-1 levels were measured by enzyme-linked immunosorbent assay in patients undergoing hepatectomy. |
| Molecular Weight | 686.64 |
| Formula | C25H44F6N6O9 |
| Smiles | CC(C)C[C@@H](C(N)=O)NC([C@H](CCCCN)NC([C@H](CO)NC([C@@H](N)CC(C)C)=O)=O)=O.OC(C(F)(F)F)=O.OC(C(F)(F)F)=O |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| Solubility Information | DMSO: 27.5 mg/mL (40.05 mM), Sonication is recommended.  | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy LSKL, Inhibitor of Thrombospondin TSP-1 2TFA | purchase LSKL, Inhibitor of Thrombospondin TSP-1 2TFA | LSKL, Inhibitor of Thrombospondin TSP-1 2TFA cost | order LSKL, Inhibitor of Thrombospondin TSP-1 2TFA | LSKL, Inhibitor of Thrombospondin TSP-1 2TFA chemical structure | LSKL, Inhibitor of Thrombospondin TSP-1 2TFA in vivo | LSKL, Inhibitor of Thrombospondin TSP-1 2TFA formula | LSKL, Inhibitor of Thrombospondin TSP-1 2TFA molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.